Oncternal Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Oncternal Therapeutics' es Jim Breitmeyer , nombrado en Jun 2019, tiene una permanencia de 4.83 años. compensación anual total es $2.41M, compuesta por 24.1% salario y 75.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.22% de las acciones de la empresa, por valor de €282.02K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 4.8 años, respectivamente.

Información clave

Jim Breitmeyer

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	24.1%
Permanencia del CEO	4.8yrs
Participación del CEO	1.2%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Breitmeyer en comparación con los beneficios de Oncternal Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$39m
Sep 30 2023	n/a	n/a	-US$42m
Jun 30 2023	n/a	n/a	-US$43m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$2m	US$580k	-US$44m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$39m
Mar 31 2022	n/a	n/a	-US$35m
Dec 31 2021	US$5m	US$557k	-US$31m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	US$780k	US$530k	-US$17m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$37m
Dec 31 2019	US$1m	US$502k	-US$34m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$518k	US$426k	-US$7m

Compensación vs. Mercado: La compensación total de Jim($USD2.41M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.

CEO

Jim Breitmeyer (69 yo)

4.8yrs

Permanencia

US$2,407,906

Compensación

Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Breitmeyer	President	4.8yrs	US$2.41m	1.22% $ 282.0k
Salim Yazji	Chief Medical Officer	2.9yrs	US$962.47k	0.24% $ 55.3k
Richard Vincent	CFO & Treasurer	4.8yrs	US$1.98m	0.27% $ 63.3k
Rajesh Krishnan	Chief Technical & Scientific Officer	3.3yrs	sin datos	0.082% $ 18.9k
Chase Leavitt	General Counsel & Secretary	3yrs	sin datos	0.16% $ 36.5k
Pablo Urbaneja	Senior Vice President of Corporate Development	2.8yrs	sin datos	sin datos
Anita Wiseth	Senior Vice President of Human Resources	less than a year	sin datos	sin datos

3.0yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GTU se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Breitmeyer	President	4.8yrs	US$2.41m	1.22% $ 282.0k
Michael Carter	Independent Director	17.9yrs	US$90.21k	0.14% $ 31.8k
Daniel Kisner	Independent Director	4.8yrs	US$80.71k	0.022% $ 5.2k
William LaRue	Independent Director	4.8yrs	US$80.21k	0.053% $ 12.2k
David Hale	Independent Chairman of the Board	4.8yrs	US$126.81k	0.027% $ 6.1k
Rosemary Mazanet	Independent Director	3.3yrs	US$72.21k	0.0051% $ 1.2k
Thomas Kipps	Scientific Advisor	no data	sin datos	sin datos
Charles Theuer	Independent Director	4.8yrs	US$72.21k	0.031% $ 7.2k
Robert Wills	Non-Independent Director	4.8yrs	US$68.21k	0.26% $ 59.5k
Marcela Maus	Cell Therapy Scientific Advisory Board Member	2.4yrs	sin datos	sin datos
Gunnar Kaufmann	Prostate Cancer & Cell Therapy Scientific Advisory Board Member	1.3yrs	US$941.21k	0.068% $ 15.8k
Xin Nakanishi	Independent Director	4.8yrs	US$68.21k	0.0039% $ 895.2

4.8yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de GTU se considera experimentada (4.8 años de antigüedad promedio).

Oncternal Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors

Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors

Recent updates

Oncternal Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2022)

Oncternal Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

New major risk - Financial position

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.23 loss in 2Q 2022)

Oncternal Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.20 loss in 1Q 2022)

Full year 2022 earnings released: US$0.84 loss per share (vs US$0.64 loss in FY 2021)

Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors

Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors

Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 loss in 3Q 2021)

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Oncternal Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma

Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Oncternal Therapeutics, Inc. Submitted an Investigational New Drug Application (“IND”) for ONCT-808

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.16 loss in 2Q 2021)

Oncternal Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

High number of new directors

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in Combination with Ibrutinib for Patients with MCL

Oncternal Therapeutics, Inc. Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At Asco 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.12 loss in 1Q 2021)

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At ASH 2021

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.22 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.34 loss in 2Q 2020)

Independent Director Man Cho has left the company

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib At ASCO 2021

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.31 loss in 1Q 2020)

New 90-day high: €6.95

Revenue beats expectations

Full year 2020 earnings released: US$0.85 loss per share (vs US$3.31 loss in FY 2019)

Oncternal Therapeutics, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €5.45

Oncternal Therapeutics, Inc. Appoints Rosemary Mazanet as a Class I Director

Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from Russell 2000 Dynamic Index

Oncternal Therapeutics, Inc. and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

Oncternal Therapeutics, Inc. Announces Updated Interim Clinical Data from the Ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib Targeting ROR1 for Leukemia and Lymphoma) Clinical Trial

Oncternal Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.500002 million.

Oncternal Therapeutics, Inc. Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting

New 90-day high: €2.90

Third quarter 2020 earnings released: US$0.22 loss per share

New 90-day low: €1.42

Oncternal Therapeutics, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma

New 90-day low: €1.57

Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020

Independent Director recently bought €126k worth of stock

New 90-day low - €1.70

Oncternal Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.500001 million.